TScan Therapeutics
TCRX
60 hedge funds and large institutions have $35.1M invested in TScan Therapeutics in 2026 Q2 according to their latest regulatory filings, with 7 funds opening new positions, 23 increasing their positions, 12 reducing their positions, and 7 closing their positions.
92% more repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 12
7% more capital invested
Capital invested by funds: $32.8M → $35.1M (+$2.3M)
0% more funds holding
Funds holding: 60 → 60 (0)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
0% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 7
3.09% less ownership
Funds ownership: 61.77% → 58.68% (-3.1%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Acadian Asset Management
Boston,
Massachusetts
|
+$1.18M |
| 2 |
BFM
Boothbay Fund Management
New York
|
+$823K |
| 3 |
Two Sigma Investments
New York
|
+$789K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$736K |
| 5 |
KCM
Kalehua Capital Management
Dallas,
Texas
|
+$485K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Aberdeen Group
Edinburgh,
United Kingdom
|
-$927K |
| 2 |
BlackRock
New York
|
-$902K |
| 3 |
Millennium Management
New York
|
-$316K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$142K |
| 5 |
NMC
Nine Masts Capital
Central,
Hong Kong
|
-$42.2K |
TCRX Hedge Fund Activity: Q2 2026 in Review
60 of the 8,318 institutional investors tracked by Wall St. Rank reported a position in TScan Therapeutics (TCRX) for Q2 2026, worth a combined $35.1M — up 7% from $32.8M a quarter earlier.
Fund positioning in TCRX was balanced in Q2 2026: 7 funds opened new positions, 7 closed out, 23 added to existing stakes and 12 trimmed.
The largest buyer was Acadian Asset Management, adding an estimated $1.18M. The largest seller was Aberdeen Group, exiting entirely with an estimated $927K sold.
- 60 institutional investors held TScan Therapeutics (TCRX) as of Q2 2026, unchanged from Q1 2026.
- Funds reported $35.1M of TScan Therapeutics stock for Q2 2026, up 7% quarter-over-quarter.
- 7 funds opened new TScan Therapeutics positions in Q2 2026 and 7 closed out, a net change of 0 holders.
- The largest TScan Therapeutics buyer in Q2 2026 was Acadian Asset Management, an estimated $1.18M added.
- The largest TScan Therapeutics seller in Q2 2026 was Aberdeen Group, an estimated $927K sold.
Based on aggregated 13F filings for Q2 2026.